Thiotepa (NSC-6396) and dimethyl sulfoxide (NSC-763) in the treatment of renal cell carcinoma

    loading  Checking for direct PDF access through Ovid


FIFTEEN PATIENTS with documented metastatic renal cell carcinoma were treated with thiotepa 20 mg/m2wk IV and 2% dimethyl sulfoxide (DMSO) in water orally to test if DMSO can augment response. Five patients had prior chemotherapy, one had prior hormonal therapy, and nine had no prior therapy. There were no objective responses seen (one patient had a mixed response) while two patients had stabilization for 53+ and 38+ weeks. DMSO has not been shown useful to augment the response rate of thiotepa in renal cell carcinoma.

    loading  Loading Related Articles